| Name | Title | Contact Details |
|---|
Founded in March 2019, the objective of The Fertility Partners (“TFP”) is to be a world class business partner of choice for leading North-American IVF clinicians with the goal of achieving global best clinical outcomes, an international reputation for excellence and exceptional patient experiences. TFP will provide partner clinics with back office support and a collaborative synergistic medical-scientific, professional and business environment.
Seneca Healthcare District is a Chester, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring. Volition`s research and development activities are centered in Belgium, with an innovation laboratory in California and additional offices in Texas, London, and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
At Tegria, we believe that the right technology and tools can help make care more effective for more people. Launched in 2020 with support from Providence, one of the country`s largest health systems, Tegria combines innovative technologies and services to create powerful solutions that simplify healthcare for everyone involved. We built Tegria to make a difference, not only for our customers, but for our communities. We deliver complete solutions to streamline the process of receiving and delivering care, from first visit to follow-up and beyond.